278 related articles for article (PubMed ID: 15979458)
1. Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth.
Hamano Y; Kalluri R
Biochem Biophys Res Commun; 2005 Jul; 333(2):292-8. PubMed ID: 15979458
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin.
Folkman J
Sci STKE; 2006 Sep; 2006(354):pe35. PubMed ID: 17003465
[TBL] [Abstract][Full Text] [Related]
3. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
4. Chapter 1. Molecular mechanism of type IV collagen-derived endogenous inhibitors of angiogenesis.
Cooke VG; Kalluri R
Methods Enzymol; 2008; 444():1-19. PubMed ID: 19007658
[TBL] [Abstract][Full Text] [Related]
5. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for the functions of endogenous angiogenesis inhibitors.
Grant MA; Kalluri R
Cold Spring Harb Symp Quant Biol; 2005; 70():399-410. PubMed ID: 16869777
[TBL] [Abstract][Full Text] [Related]
7. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties.
Maeshima Y; Colorado PC; Kalluri R
J Biol Chem; 2000 Aug; 275(31):23745-50. PubMed ID: 10837460
[TBL] [Abstract][Full Text] [Related]
8. Targeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivo.
Mueller J; Gaertner FC; Blechert B; Janssen KP; Essler M
Mol Cancer Res; 2009 Jul; 7(7):1078-85. PubMed ID: 19584266
[TBL] [Abstract][Full Text] [Related]
9. Type IV collagen-derived angiogenesis inhibitors.
Mundel TM; Kalluri R
Microvasc Res; 2007; 74(2-3):85-9. PubMed ID: 17602710
[TBL] [Abstract][Full Text] [Related]
10. Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.
Pernasetti F; Nickel J; Clark D; Baeuerle PA; Van Epps D; Freimark B
Int J Oncol; 2006 Dec; 29(6):1371-9. PubMed ID: 17088974
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of tumor angiogenesis by tumstatin: insights into signaling mechanisms and implications in cancer regression.
Sudhakar A; Boosani CS
Pharm Res; 2008 Dec; 25(12):2731-9. PubMed ID: 18551250
[TBL] [Abstract][Full Text] [Related]
12. [Angiogenesis and its regulation].
Iwaguchi T
Gan To Kagaku Ryoho; 1993 Jan; 20(1):1-9. PubMed ID: 7678486
[TBL] [Abstract][Full Text] [Related]
13. Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis.
Boosani CS; Mannam AP; Cosgrove D; Silva R; Hodivala-Dilke KM; Keshamouni VG; Sudhakar A
Blood; 2007 Aug; 110(4):1168-77. PubMed ID: 17426256
[TBL] [Abstract][Full Text] [Related]
14. Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity.
Eikesdal HP; Sugimoto H; Birrane G; Maeshima Y; Cooke VG; Kieran M; Kalluri R
Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15040-5. PubMed ID: 18818312
[TBL] [Abstract][Full Text] [Related]
15. Expression, purification, and bioactivity of human tumstatin from Escherichia coli.
Gu Q; Zhang T; Luo J; Wang F
Protein Expr Purif; 2006 Jun; 47(2):461-6. PubMed ID: 16503164
[TBL] [Abstract][Full Text] [Related]
16. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin.
Hamano Y; Zeisberg M; Sugimoto H; Lively JC; Maeshima Y; Yang C; Hynes RO; Werb Z; Sudhakar A; Kalluri R
Cancer Cell; 2003 Jun; 3(6):589-601. PubMed ID: 12842087
[TBL] [Abstract][Full Text] [Related]
17. [Angiogenesis and anti-angiogenesis in human neoplasms. Recent developments and the therapeutic prospects].
Vacca A; Ribatti D; Pellegrino A; Dammacco F
Ann Ital Med Int; 2000; 15(1):7-19. PubMed ID: 10842887
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific expression of the RGD-alpha3(IV)NC1 domain suppresses endothelial tube formation and tumor growth in mice.
Miyoshi T; Hirohata S; Ogawa H; Doi M; Obika M; Yonezawa T; Sado Y; Kusachi S; Kyo S; Kondo S; Shiratori Y; Hudson BG; Ninomiya Y
FASEB J; 2006 Sep; 20(11):1904-6. PubMed ID: 16877525
[TBL] [Abstract][Full Text] [Related]
19. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis.
Maeshima Y; Yerramalla UL; Dhanabal M; Holthaus KA; Barbashov S; Kharbanda S; Reimer C; Manfredi M; Dickerson WM; Kalluri R
J Biol Chem; 2001 Aug; 276(34):31959-68. PubMed ID: 11399763
[TBL] [Abstract][Full Text] [Related]
20. Disruption of endothelial cell interactions with the novel HU177 cryptic collagen epitope inhibits angiogenesis.
Cretu A; Roth JM; Caunt M; Akalu A; Policarpio D; Formenti S; Gagne P; Liebes L; Brooks PC
Clin Cancer Res; 2007 May; 13(10):3068-78. PubMed ID: 17505010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
